Benitec Biopharma Limited Company Profile (NASDAQ:BNTC)

About Benitec Biopharma Limited (NASDAQ:BNTC)

Benitec Biopharma Limited logoBenitec Biopharma Limited is a biotechnology company. The Company is engaged in progressing programs through the clinic; the commercialization of its Intellectual Property (IP); development of its therapeutic pipeline and pre-clinical programs, and funding, and protecting and building the IP estate. Its In-house product candidates include TT-034, BB-HB-331, BB-AMD-211 and ddRNAi therapeutic. It is focused on commercialization by licensing and partnering of patents and licenses in biotechnology, in functional genomics, with applications in biomedical research and human therapeutics. It has a pipeline of in-house and partnered therapeutic programs based on its patented gene-silencing technology, deoxyribonucleic acid (DNA)-directed ribonucleic acid interference (ddRNAi). The Company is engaged in developing treatments for chronic human conditions, such as hepatitis B, wet age-related macular degeneration (AMD), and oculopharyngeal muscular dystrophy (OPMD) based on this technology.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Symbol: NASDAQ:BNTC
  • CUSIP: N/A
  • Web: www.benitec.com
Capitalization:
  • Market Cap: $26.05 million
  • Outstanding Shares: 10,257,000
Average Prices:
  • 50 Day Moving Avg: $2.27
  • 200 Day Moving Avg: $2.31
  • 52 Week Range: $1.30 - $5.48
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -10.58
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $8.93 million
  • Price / Sales: 2.92
  • Book Value: $1.68 per share
  • Price / Book: 1.51
Profitability:
  • EBITDA: ($4,190,000.00)
  • Net Margins: -50.76%
  • Return on Equity: -26.97%
  • Return on Assets: -25.55%
Debt:
  • Current Ratio: 19.88%
Misc:
  • Average Volume: 65,183 shs.
  • Beta: 3.49
  • Short Ratio: 3.57
 

Frequently Asked Questions for Benitec Biopharma Limited (NASDAQ:BNTC)

What is Benitec Biopharma Limited's stock symbol?

Benitec Biopharma Limited trades on the NASDAQ under the ticker symbol "BNTC."

When will Benitec Biopharma Limited make its next earnings announcement?

Benitec Biopharma Limited is scheduled to release their next quarterly earnings announcement on Tuesday, November, 28th 2017. View Earnings Estimates for Benitec Biopharma Limited.

Who are some of Benitec Biopharma Limited's key competitors?

Who are Benitec Biopharma Limited's key executives?

Benitec Biopharma Limited's management team includes the folowing people:

  • Gregory West, Chief Executive Officer, Company Secretary
  • Bryan Dulhunty, Chief Financial Officer
  • Cliff Holloway, Chief Business and Operating Officer
  • Michael Graham, Chief Scientific Officer
  • Peter Damian Francis, Independent Non-Executive Chairman of the Board
  • Kevin Buchi CPA, Director
  • Jerel A. Banks M.D., Ph.D., Non-Executive Director
  • Megan Joan Boston, Non-Executive Director
  • John C. Chiplin Ph.D., Non-Executive Independent Director

When did Benitec Biopharma Limited IPO?

(BNTC) raised $0 in an initial public offering (IPO) on Thursday, August 6th 2015. The company issued 0 shares at a price of $0.00 per share. BMO Capital Markets and Maxim Group LLC acted as the underwriters for the IPO and Roth Capital Partners was co-manager.

How do I buy Benitec Biopharma Limited stock?

Shares of Benitec Biopharma Limited can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Benitec Biopharma Limited's stock price today?

One share of Benitec Biopharma Limited stock can currently be purchased for approximately $2.54.


MarketBeat Community Rating for Benitec Biopharma Limited (NASDAQ BNTC)
Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  37 (Vote Outperform)
Underperform Votes:  35 (Vote Underperform)
Total Votes:  72
MarketBeat's community ratings are surveys of what our community members think about Benitec Biopharma Limited and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Benitec Biopharma Limited (NASDAQ:BNTC) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: N/A
Consensus Price Target History for Benitec Biopharma Limited (NASDAQ:BNTC)
Price Target History for Benitec Biopharma Limited (NASDAQ:BNTC)
Analysts' Ratings History for Benitec Biopharma Limited (NASDAQ:BNTC)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/30/2017Maxim GroupReiterated RatingHoldMediumView Rating Details
(Data available from 10/22/2015 forward)

Earnings

Earnings History for Benitec Biopharma Limited (NASDAQ:BNTC)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Benitec Biopharma Limited (NASDAQ:BNTC)
Current Year EPS Consensus Estimate: $-0.10 EPS
Next Year EPS Consensus Estimate: $-0.24 EPS

Dividends

Dividend History for Benitec Biopharma Limited (NASDAQ:BNTC)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Benitec Biopharma Limited (NASDAQ:BNTC)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Benitec Biopharma Limited (NASDAQ:BNTC)
Latest Headlines for Benitec Biopharma Limited (NASDAQ:BNTC)
Source:
Loading headlines, please wait.

Social

Chart

Benitec Biopharma Limited (BNTC) Chart for Sunday, October, 22, 2017

This page was last updated on 10/22/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.